Serri, Sardinia

Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform

Retrieved on: 
Tuesday, January 2, 2024
Research, Doctor of Philosophy, Serri, Sardinia, Endoscopy, Organization, SAN, Aviation, AstraZeneca, Therapy, Pharmaceutical industry

SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc .

Key Points: 
  • SAN DIEGO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc .
  • (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that its BioJet™ Systemic Oral Delivery Platform has met key performance milestones as part of its research collaboration with AstraZeneca.
  • The BioJet platform is designed to use needle-free, liquid jet injection to deliver drug into the small intestine for systemic absorption.
  • BioJet devices were administered endoscopically, which is typical in a porcine model, and released for autonomous activation,” said Sharat Singh, PhD, Head of Research at Biora Therapeutics.

Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors

Retrieved on: 
Monday, December 18, 2023
Gibson Dunn, Highbridge Capital Management, Ropes & Gray, Davidson Kempner Capital Management, SAN, Therapy, King & Spalding, Serri, Sardinia, Security (finance)

SAN DIEGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced an agreement with institutional investors Athyrium Capital Management, Davidson Kempner Capital Management, and Highbridge Capital Management to reduce the company’s net debt by 60% through a convertible note exchange which also brings $16.7 million in new capital.

Key Points: 
  • SAN DIEGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced an agreement with institutional investors Athyrium Capital Management, Davidson Kempner Capital Management, and Highbridge Capital Management to reduce the company’s net debt by 60% through a convertible note exchange which also brings $16.7 million in new capital.
  • Between the note exchange implemented in September and today’s transaction, we achieved a 75% overall reduction in net debt.
  • This represents substantial progress toward our goal to optimize our capital structure to align with the current company profile,” said Eric d’Esparbes, Chief Financial Officer of Biora Therapeutics.
  • “The additional capital investment from three established institutional investors demonstrates continued support for our innovative technologies.

Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes

Retrieved on: 
Thursday, October 5, 2023
Pharmacokinetics, European Association for the Study of Diabetes, Doctor of Philosophy, Animal, Therapy, IV, SAN, Aviation, Serri, Sardinia, Pharmaceutical industry, Diabetes

(Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, presented data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platform in a short oral discussion titled “Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1 Receptor Agonist Delivered through the BioJet™ Biotherapeutic Delivery Platform in Swine” at the 59th annual meeting of the European Association for the Study of Diabetes, in Hamburg, Germany.

Key Points: 
  • (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, presented data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platform in a short oral discussion titled “Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1 Receptor Agonist Delivered through the BioJet™ Biotherapeutic Delivery Platform in Swine” at the 59th annual meeting of the European Association for the Study of Diabetes, in Hamburg, Germany.
  • “In recent studies, we assessed the bioavailability of semaglutide when delivered via our autonomous next-generation BioJet device in a porcine model.
  • The studies included single, approximately 1 mg doses of semaglutide in a liquid formulation delivered via the BioJet device.
  • The presentation can be viewed on the European Association for the Study of Diabetes website and is also available on the Biora Therapeutics website .

Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program

Retrieved on: 
Monday, September 25, 2023
Serri, Sardinia, Clinical trial, Pharmacokinetics, Ulcerative colitis, Colon, Investigational New Drug, MD, Patient, SAN, Toxicology, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Food, Safety, Pharmaceutical industry

SAN DIEGO, Sept. 25, 2023 (GLOBE NEWSWIRE) --  Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA). The IND application supports the next phase of development of BT-600, a drug/device combination designed to use Biora’s NaviCap™ ingestible drug delivery device with a proprietary liquid formulation of tofacitinib, for the treatment of moderate to severe ulcerative colitis.

Key Points: 
  • (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA).
  • “Today’s announcement is an important milestone for Biora Therapeutics.
  • The IND application for BT-600 includes extensive manufacturing, preclinical, human device function, and toxicology data to support a first-in-human clinical trial for BT-600.
  • The FDA will review the application and determine the acceptability of the data before Biora begins its first clinical trial for BT-600.

Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer

Retrieved on: 
Monday, September 11, 2023
Translation, Bachelor of Science in Human Biology, IPO, Employment, Research and development, RSU, Therapy, Doctor of Philosophy, Gastrointestinal tract, Interface, IBD, Serri, Sardinia, Head, Quality of life, Innovation, CMO, Biomedical engineering, Immunotherapy, Sale, Inflammatory bowel disease, Patient, Mitchell Jones, Corporation, McGill University, GI, Compensated emancipation, Inflammation, Nursing, Medical device, Pharmaceutical industry

Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the appointment of Mitchell Jones, M.D., Ph.D., as Chief Medical Officer.

Key Points: 
  • Carlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the appointment of Mitchell Jones, M.D., Ph.D., as Chief Medical Officer.
  • “We are delighted to welcome Mitch to Palisade Bio as our Chief Medical Officer.
  • Finley, Chief Executive Officer of Palisade Bio.
  • Dr. Jones added, “This is truly an exciting time for Palisade Bio.

Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

Retrieved on: 
Monday, September 11, 2023
Therapy, Conference, SAN, Serri, Sardinia, Pharmaceutical industry, Fishing

SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc .

Key Points: 
  • SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc .
  • (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York City.
  • The Biora presentation will begin on Wednesday, September 13, at 11:00 AM Eastern time.
  • Biora management will also participate in one-on-one meetings during the conference.

Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 14, 2023
Human, American Diabetes Association, Therapy, Comparison, IBD, Aviation, European Association for the Study of Diabetes, Toxicity, Ulcerative colitis, Colon, Patent, Patient, SAN, Webcast, IND, Serri, Sardinia, Disease, Pharmaceutical industry, 3D printing, Medical device, Clothing, Reinsurance, Diabetes

SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • NaviCap™ targeted oral delivery platform on track for September IND filing; achieved successful device function study results in humans with phase 1-ready device
    SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the second quarter ended June 30, 2023.
  • “During the second quarter, we continued development of our BioJet™ platform, which has shown category-leading oral bioavailability of large molecules.
  • Also during the second quarter, Biora presented data at the American Diabetes Association assessing the delivery of semaglutide via the BioJet device in an animal model.
  • Biora Therapeutics will host a webcast and conference call to discuss the second quarter financial results and provide a corporate update today, Monday, August 14, 2023 at 4:30 PM Eastern time / 1:30 PM Pacific time.

Biora Therapeutics Announces Clinical Device Performance Study Results for its NaviCap™ Targeted Oral Delivery Platform

Retrieved on: 
Thursday, July 27, 2023
Therapy, Radionuclide, IBD, Doctor of Philosophy, Ulcerative colitis, Colon, Nuclear medicine, MD, Patient, SAN, GI, IND, Serri, Sardinia, Safety, Pharmaceutical industry, Medical device

(Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced progress with its latest clinical device performance study, evaluating the device function and safety of its NaviCap™ targeted oral delivery platform.

Key Points: 
  • (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced progress with its latest clinical device performance study, evaluating the device function and safety of its NaviCap™ targeted oral delivery platform.
  • The NaviCap platform uses an ingestible device designed for targeted delivery of therapeutics to improve treatment of IBD.
  • Once swallowed, Biora’s GItrac™ autolocation technology enables the device to autonomously identify targeted locations in the GI tract and release its payload.
  • Biora’s BT-603 clinical device performance study was designed to evaluate the safety and tolerability of its phase 1-ready NaviCap device and the device’s localization and delivery function in healthy volunteers.

Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the American Diabetes Association 83rd Scientific Sessions

Retrieved on: 
Monday, June 26, 2023
American Diabetes Association, Animal, Semaglutide, Aviation, Doctor of Philosophy, MD, Patient, Pharmacokinetics, SAN, Therapy, ADA, Serri, Sardinia, Pharmaceutical industry

“In this preclinical study, we assessed the bioavailability of semaglutide when delivered via our BioJet device in a porcine model.

Key Points: 
  • “In this preclinical study, we assessed the bioavailability of semaglutide when delivered via our BioJet device in a porcine model.
  • Following administration of semaglutide, the average oral bioavailability was 37%, ranging from 19% to 60% (CV: 40%).
  • All dosed animals showed detectable drug levels up to ten days after administration,” said Sharat Singh, PhD, Head of Research at Biora Therapeutics.
  • “Oral delivery of large molecules presents many challenges,” said Ariella Kelman, MD, Chief Medical Officer of Biora Therapeutics.

Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 15, 2023
Diabetes, Comparison, Semaglutide, Q2, Adalimumab, Aviation, Ulcerative colitis, ATM, Animal, SAN, Blood, Webcast, Therapy, IND, Serri, Sardinia, Safety, Pharmaceutical industry, Vaccine, Reinsurance

SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Completed execution of toxicology study for NaviCap™ BT-600 program with no adverse events indicated in preliminary data; on track to file IND in Q3 2023
    SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today provided a corporate update and reported financial results for the first quarter ended March 31, 2023.
  • While results are still being analyzed, the company has received the majority of the data, and has observed no adverse events or safety signals.
  • “With our BioJet™ systemic delivery platform, we recently conducted a round of preclinical testing with one of our collaborators, for which we are awaiting results.
  • Biora Therapeutics will host a webcast and conference call to discuss the first quarter financial results and provide a corporate update today, Monday, May 15, 2023, at 4:30 PM Eastern time / 1:30 PM Pacific time.